| |
|
Headlines:
|
 |
Back to Conference Highlights
Crestor® in African-American patients better in
controlling high cholesterol
6/11/04 - 10/11/04, New Orleans, LA
|
|
|
Scientific Sessions, the largest cardiovascular meeting
in the world, is being held in New Orleans Nov. 6–10.
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
NEW ORLEANS (November 9, 2004) -- New data
presented today at the American Heart Association's Annual
Scientific Sessions showed that AstraZeneca's CRESTOR® (rosuvastatin
calcium) at 10 and 20 mg reduced LDL-C or "bad" cholesterol by
37 and 46 percent, compared to 32 and 39 percent at similar
doses with
atorvastatin (Lipitor) in African-American patients.
CRESTOR also brought more patients
in this study to National Cholesterol Education Program Adult
Treatment Panel III (ATP III) LDL-C goals than
atorvastatin (Lipitor)at
milligram-equivalent doses of 10 and 20 mg. ARIES (African
American Rosuvastatin Investigation of Efficacy and Safety) is
the first-ever large-scale, prospective trial exclusively
designed to compare the effects of statins in African-American
patients, who have generally been underrepresented in clinical
trials.
"As an African American physician who treats a large number of
African-American patients, the ARIES trial represents an
opportunity to demonstrate the efficacy and safety of statins in
this high-risk, undertreated and underserved population," said
Dr. Keith C. Ferdinand, clinical cardiologist and medical
director of Heartbeats Life Center and the lead investigator for
ARIES. "ARIES is the first trial to demonstrate superiority in
lowering LDL-cholesterol (bad cholesterol) in this population
using rosuvastatin (CRESTOR) compared to
atorvastatin (Lipitor), comparing
equal doses of each."
ARIES is a six-week, randomized, controlled, open-label,
multi-center trial designed to evaluate the efficacy of CRESTOR
and
atorvastatin (Lipitor)in African Americans with elevated cholesterol.
After a six-week dietary lead-in, 774 African-American adults
with hypercholesterolemia were randomized to one of four
open-label treatments for six weeks: CRESTOR 10 or 20 mg or
atorvastatin (Lipitor)10 or 20 mg. Results showed CRESTOR 10 and 20 mg
reduced LDL-C by 37 and 46 percent respectively compared with 32
and 39 percent for
atorvastatin (Lipitor)at the same dosages (p<0.017).
The data also showed that 66 and 79 percent of the patients
treated with CRESTOR 10 and 20 mg respectively reached their
NCEP ATP III cholesterol goals compared to 58 and 62 percent for
the patients treated with
atorvastatin (Lipitor)10 and 20 mg
respectively. Treatments used in the ARIES study were well
tolerated.
Additional data from ARIES demonstrated
CRESTOR 10 and 20 mg increased HDL-C by 7 and 6.5 percent
compared with 5.6 and 3.7 percent with
atorvastatin (Lipitor)10 and 20
mg. CRESTOR 10 mg produced significantly greater increases than
20 mg of
atorvastatin (Lipitor)(p<0.017)
CRESTOR 10 and 20 mg reduced non-HDL-C by 34 and 42 percent
compared with 30 and 36 percent for
atorvastatin (Lipitor)at the same
dosages (p<0.017)
CRESTOR 10 and 20 mg reduced total cholesterol by 27 and 33
percent compared with 23 and 29 percent for
atorvastatin (Lipitor)10 and
20 mg (p<0.017)
African Americans and Elevated Cholesterol
According to the American Heart Association, approximately 42
percent of the African-American population has high cholesterol,
and an estimated 45 percent has elevated LDL-C levels.
Additionally, according to the National Center for Chronic
Disease Prevention and Health Promotion's Risk Factor
Surveillance System (BRFSS), an estimated 26 percent of the
African-American population has never had their cholesterol
levels checked.
|
|
|
|
Are you a doctor or a nurse?
Do you want to join the Doctors Lounge online medical community?
Participate in editorial activities (publish, peer review, edit) and
give a helping hand to the largest online community of patients.
Click on the link below to see the requirements:
Doctors Lounge Membership
Application |
|
Sources
American Heart Association - scientific sessions - 6/11/04 - 10/11/04, New Orleans, LA Legal Disclaimer
The materials presented here were prepared by independent authors
under the editorial supervision of The Doctors Lounge, and do not represent a
publication of the American Heart Association. These
materials and the related activity are not sanctioned by the American
Heart Association or the commercial supporter of the
conference, and do not constitute an official part of that conference.
The material presented here does not reflect the views of The Doctors
Lounge or
the companies providing unrestricted educational grants. These materials
may discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
health care professional should be consulted before using any
therapeutic product discussed. All readers or continuing education
participants should verify all information and data before treating
patients or employing any therapies described in this educational
activity.
Copyright © 2004 The Doctors Lounge.
| Article reviewed by: |
Dr. Tamer Fouad, M.D.
|
|
|
send
to a friend
printer
friendly version
